SM
ALBO

Sabby Management’s Albireo Pharma Inc ALBO Stock Holding History

Sabby Management’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-101
Closed -$1.27M – 242
2013
Q2 		$1.27M Buy
+101
New +$10.5K 0.08% 108

Other funds holding ALBO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sabby Management's ALBO Position: Q2 2016 in Review

Sabby Management sold out of Albireo Pharma Inc (ALBO) in Q2 2016, closing a stake of 11,917 shares — an estimated $118K sold.

Sabby Management first reported a position in ALBO in Q2 2014 and held it in 8 quarters. The position peaked at $1.18M in Q2 2015. 24 funds tracked by Wall St. Rank hold ALBO as of Q2 2016.

  • Sabby Management reported no remaining Albireo Pharma Inc position as of Q2 2016 after selling out during the quarter.
  • Sabby Management sold 11,917 Albireo Pharma Inc shares in Q2 2016, an estimated $118K.
  • Sabby Management first reported a position in Albireo Pharma Inc in Q2 2014 and held it in 8 quarters.
  • Sabby Management's Albireo Pharma Inc position peaked at $1.18M in Q2 2015.
  • 24 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.